This page lists the SEC filings reported by Deep Track Capital, LP.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G | 2023-11-02 | Deep Track Capital, LP | Ambrx Biopharma, Inc. | 3,710,412 | 5.6% | EDGAR |
| SC 13G | 2023-10-30 | Deep Track Capital, LP | Abivax S.A. | 4,297,438 | 6.1% | EDGAR |
| SC 13G | 2023-10-27 | Deep Track Capital, LP | Tourmaline Bio, Inc. | 1,815,854 | 8.9% | EDGAR |
| SC 13G | 2023-10-23 | Deep Track Capital, LP | RAPT Therapeutics, Inc. | 1,991,403 | 5.8% | EDGAR |
| SC 13G | 2023-10-02 | Deep Track Capital, LP | ANAPTYSBIO, INC | 1,360,176 | 5.1% | EDGAR |
| SC 13G | 2023-09-29 | Deep Track Capital, LP | HilleVax, Inc. | 2,900,000 | 6.1% | EDGAR |
| SC 13G | 2023-08-04 | Deep Track Capital, LP | Editas Medicine, Inc. | 4,493,416 | 5.5% | EDGAR |
| SC 13G | 2023-07-28 | Deep Track Capital, LP | Terns Pharmaceuticals, Inc. | 3,560,000 | 6.3% | EDGAR |
| SC 13G | 2023-07-24 | Deep Track Capital, LP | Apogee Therapeutics, Inc. | 3,023,456 | 8.9% | EDGAR |
| SC 13G | 2023-06-30 | Deep Track Capital, LP | Aeglea BioTherapeutics, Inc. | 7,258,056 | 10.0% | EDGAR |
| SC 13G | 2023-06-15 | Deep Track Capital, LP | Zura Bio Ltd | 4,205,000 | 9.4% | EDGAR |
| SC 13G | 2023-05-19 | Deep Track Capital, LP | DYNAVAX TECHNOLOGIES CORP | 6,556,180 | 5.1% | EDGAR |
| SC 13G | 2023-04-14 | Deep Track Capital, LP | NEKTAR THERAPEUTICS | 12,302,237 | 6.5% | EDGAR |
| SC 13G | 2023-04-14 | Deep Track Capital, LP | SpringWorks Therapeutics, Inc. | 3,254,132 | 5.2% | EDGAR |
| SC 13G | 2023-03-20 | Deep Track Capital, LP | Orchard Therapeutics plc | 19,125,150 | 10.0% | EDGAR |
| SC 13G | 2023-03-20 | Deep Track Capital, LP | PLIANT THERAPEUTICS, INC. | 3,104,507 | 5.3% | EDGAR |
| SC 13G | 2023-02-24 | Deep Track Capital, LP | Nurix Therapeutics, Inc. | 2,717,171 | 5.8% | EDGAR |
| SC 13G/A | 2023-02-14 | Deep Track Capital, LP | Acumen Pharmaceuticals, Inc. | 3,952,000 | 9.7% | EDGAR |
| SC 13G/A | 2023-02-14 | Deep Track Capital, LP | AGENUS INC | 27,000,000 | 8.9% | EDGAR |
| SC 13G/A | 2023-02-14 | Deep Track Capital, LP | ALBIREO PHARMA, INC. | 1,704,000 | 8.2% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.